Particularly as a result of scientific and technical progress, the definitions and scope of Directive 2001/83/EC should be clarified in order to achieve high standards for the quality, safety and efficacy of medicinal products for human use. In order to take account both of the emergence of new therapies and of the growing number of so-called "borderline" products between the medicinal product sector and other sectors, the definition of "medicinal product" should be modified so as to avoid any doubt as to the applicable legislation when a product, whilst fully falling within the definition of a medicinal product, may also fall within the definition of other regulated products. This definition should specify the type of action that the medicinal product may exert on physiological functions. This enumeration of actions will also make it possible to cover medicinal products such as gene therapy, radiopharmaceutical products as well as certain medicinal products for topical use. Also, in view of the characteristics of pharmaceutical legislation, provision should be made for such legislation to apply. With the same objective of clarifying situations, where a given product comes under the definition of a medicinal product but could also fall within the definition of other regulated products, it is necessary, in case of doubt and in order to ensure legal certainty, to state explicitly which provisions have to be complied with. Where a product comes clearly under the definition of other product categories, in particular food, food supplements, medical devices, biocides or cosmetics, this Directive should not apply. It is also appropriate to improve the consistency of the terminology of pharmaceutical legislation.
Recital 7, Directive (EU) 2004/27
Judgment of the Court (First Chamber) of 15 January 2009. Hecht-Pharma GmbH v Staatliches Gewerbeaufsichtsamt Lüneburg.Decision
Recitals 2, 3, 4 and 7 in the preamble to Directive 2004/27 state that: ‘(2) The Community legislation so far adopted has made a major contribution to the achievement of the objective of the free and safe movement of medicinal products …
15 Jan 2009 · 62007CJ0140
Judgment of the Court (Seventh Chamber) of 19 January 2023. L. GmbH and H. Ltd v Bundesrepublik Deutschland.Decision
Directive 2004/27, which introduced that provision into Directive 2001/83, states, in recital 7, that ‘the definitions and scope of Directive 2001/83/EC should be clarified in order to achieve high standards for the quality, safety and …
19 Jan 2023 · 62021CJ0495
Judgment of the Court (First Chamber), 13 March 2014. Octapharma France SAS v Agence nationale de sécurité du médicament et des produits de Decision
Directive 2004/27, which amends Directive 2001/83, states, in recital 7 in its preamble, that ‘the definitions and scope of Directive 2001/83/EC should be clarified in order to achieve high standards for the quality, safety and efficacy …
13 Mar 2014 · 62012CJ0512
Judgment of the Court (Third Chamber) of 16 July 2015. Abcur AB v Apoteket Farmaci AB and Apoteket AB.Decision
According to recital 7 in the preamble to that directive, ‘[p]articularly as a result of scientific and technical progress, the definitions and scope of Directive 2001/83/EC should be clarified in order to achieve high standards for the …
16 Jul 2015 · 62013CJ0544
Judgment of the Court (Fifth Chamber) of 13 March 2025. Cassella-med GmbH & Co. KG and MCM Klosterfrau Vertriebsgesellschaft mbH v Verband SDecision
As the Court has noted, Directive 2004/27, which introduced Article 2(2) into Directive 2001/83, states in recital 7 that, ‘in order to take account both of the emergence of new therapies and of the growing number of so-called …
13 Mar 2025 · 62023CJ0589
Judgment of the Court (Ninth Chamber) of 4 September 2025. Kwizda Pharma GmbH v Landeshauptmann von Wien.Decision
Recital 7 of Directive 2004/27 states: ‘… the definitions and scope of Directive [2001/83] should be clarified … In order to take account both of the emergence of new therapies and of the growing number of so-called “borderline” …
4 Sep 2025 · 62024CJ0451
Opinion of Mr Advocate General Ruiz-Jarabo Colomer delivered on 18 November 2008. Criminal proceedings against Frede Damgaard.Decision
Directive 2001/83 was amended by Directive 2004/27/EC (8) because ‘the definitions and scope of Directive 2001/83/EC should be clarified in order to achieve high standards for the quality, safety and efficacy of medicinal products for …
18 Nov 2008 · 62007CC0421
Opinion of Advocate General Campos Sánchez-Bordona delivered on 30 January 2025. SALUS Haus Dr. med Otto Greither Nachf. GmbH & Co.KG v AstrDecision
The interpretation which I propose is also consistent with the European approach to regulating medicinal products, which tends to reject the double legal classification of products (and the consequent diversity of regimes) which fit the …
30 Jan 2025 · 62023CC0618
Opinion of Advocate General Jääskinen delivered on 7 November 2013. Octapharma France SAS v Agence nationale de sécurité du médicament et deDecision
Directive 2001/83 was amended extensively by Directive 2004/27. According to recital 7 of Directive 2004/27 the definitions and scope of Directive 2001/83 needed to be clarified ‘as a result of scientific and technological progress’. …
7 Nov 2013 · 62012CC0512